XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

Greetings and welcome to the X4 Pharmaceuticals fourth quarter and full year 2024 financial and operating results conference call. (Operator Instructions) and it is now my pleasure to turn to your ...

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Findings from a phase 2 trial published in JTO Clinical and Research Reports suggest that pembrolizumab (Keytruda) plus ...

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed ...

Neutropenia is a rare side effect of clozapine, and severe cases can be life-threatening. The blood test was a necessary part of a regimen known as risk evaluation and mitigation strategies, or REMS.

The Clozapine REMS program was established in 2015 due to the risk of severe neutropenia associated with the medication. Prior to pharmacies dispensing clozapine, the FDA required patients to ...

Background: The purpose of this systematic review and meta-analysis was to evaluate the effect of a neutropenic diet and a control diet on infection and mortality rates in oncology patients with ...